New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy
Oncolytic virus (OV) therapy has emerged as a promising frontier in cancer treatment, especially for solid tumours. While immunotherapies like immune checkpoint inhibitors and CAR-T cells have demonstrated impressive results, their limitations in inducing complete tumour regression have spurred rese...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1375433/full |
| _version_ | 1797254063319941120 |
|---|---|
| author | Hanna Chowaniec Antonina Ślubowska Magdalena Mroczek Martyna Borowczyk Małgorzata Braszka Grzegorz Dworacki Grzegorz Dworacki Paula Dobosz Paula Dobosz Mateusz Wichtowski |
| author_facet | Hanna Chowaniec Antonina Ślubowska Magdalena Mroczek Martyna Borowczyk Małgorzata Braszka Grzegorz Dworacki Grzegorz Dworacki Paula Dobosz Paula Dobosz Mateusz Wichtowski |
| author_sort | Hanna Chowaniec |
| collection | DOAJ |
| description | Oncolytic virus (OV) therapy has emerged as a promising frontier in cancer treatment, especially for solid tumours. While immunotherapies like immune checkpoint inhibitors and CAR-T cells have demonstrated impressive results, their limitations in inducing complete tumour regression have spurred researchers to explore new approaches targeting tumours resistant to current immunotherapies. OVs, both natural and genetically engineered, selectively replicate within cancer cells, inducing their lysis while sparing normal tissues. Recent advancements in clinical research and genetic engineering have enabled the development of targeted viruses that modify the tumour microenvironment, triggering anti-tumour immune responses and exhibiting synergistic effects with other cancer therapies. Several OVs have been studied for breast cancer treatment, including adenovirus, protoparvovirus, vaccinia virus, reovirus, and herpes simplex virus type I (HSV-1). These viruses have been modified or engineered to enhance their tumour-selective replication, reduce toxicity, and improve oncolytic properties.Newer generations of OVs, such as Oncoviron and Delta-24-RGD adenovirus, exhibit heightened replication selectivity and enhanced anticancer effects, particularly in breast cancer models. Clinical trials have explored the efficacy and safety of various OVs in treating different cancers, including melanoma, nasopharyngeal carcinoma, head and neck cancer, and gynecologic malignancies. Notably, Talimogene laherparepvec (T-VEC) and Oncorine have. been approved for advanced melanoma and nasopharyngeal carcinoma, respectively. However, adverse effects have been reported in some cases, including flu-like symptoms and rare instances of severe complications such as fistula formation. Although no OV has been approved specifically for breast cancer treatment, ongoing preclinical clinical trials focus on four groups of viruses. While mild adverse effects like low-grade fever and nausea have been observed, the effectiveness of OV monotherapy in breast cancer remains insufficient. Combination strategies integrating OVs with chemotherapy, radiotherapy, or immunotherapy, show promise in improving therapeutic outcomes. Oncolytic virus therapy holds substantial potential in breast cancer treatment, demonstrating safety in trials. Multi-approach strategies combining OVs with conventional therapies exhibit more promising therapeutic effects than monotherapy, signalling a hopeful future for OV-based breast cancer treatments. |
| first_indexed | 2024-04-24T21:44:00Z |
| format | Article |
| id | doaj.art-b794595d426a4143b8ab05297595188d |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-24T21:44:00Z |
| publishDate | 2024-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-b794595d426a4143b8ab05297595188d2024-03-21T04:33:14ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-03-011510.3389/fimmu.2024.13754331375433New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapyHanna Chowaniec0Antonina Ślubowska1Magdalena Mroczek2Martyna Borowczyk3Małgorzata Braszka4Grzegorz Dworacki5Grzegorz Dworacki6Paula Dobosz7Paula Dobosz8Mateusz Wichtowski9Department of Immunology, Poznan University of Medical Sciences, Poznan, PolandDepartment of Biostatistics and Research Methodology, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University of Warsaw, Warsaw, PolandDepartment of Neurology, University Hospital Basel, Univeristy of Basel, Basel, SwitzerlandDepartment of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Poznan, PolandFaculty of Medical Sciences, University College London Medical School, London, United KingdomDepartment of Immunology, Poznan University of Medical Sciences, Poznan, PolandChair of Patomorphology and Clinical Immunology, Poznań University of Medical Sciences, Poznan, PolandUniversity Centre of Cancer Diagnostics, Poznan University of Medical Sciences, Poznan, PolandInstitute of Genetics and Biotechnology, Faculty of Biology, University of Warsaw, Warsaw, PolandSurgical Oncology Clinic, Institute of Oncology, Poznan University of Medical Sciences, Poznan, PolandOncolytic virus (OV) therapy has emerged as a promising frontier in cancer treatment, especially for solid tumours. While immunotherapies like immune checkpoint inhibitors and CAR-T cells have demonstrated impressive results, their limitations in inducing complete tumour regression have spurred researchers to explore new approaches targeting tumours resistant to current immunotherapies. OVs, both natural and genetically engineered, selectively replicate within cancer cells, inducing their lysis while sparing normal tissues. Recent advancements in clinical research and genetic engineering have enabled the development of targeted viruses that modify the tumour microenvironment, triggering anti-tumour immune responses and exhibiting synergistic effects with other cancer therapies. Several OVs have been studied for breast cancer treatment, including adenovirus, protoparvovirus, vaccinia virus, reovirus, and herpes simplex virus type I (HSV-1). These viruses have been modified or engineered to enhance their tumour-selective replication, reduce toxicity, and improve oncolytic properties.Newer generations of OVs, such as Oncoviron and Delta-24-RGD adenovirus, exhibit heightened replication selectivity and enhanced anticancer effects, particularly in breast cancer models. Clinical trials have explored the efficacy and safety of various OVs in treating different cancers, including melanoma, nasopharyngeal carcinoma, head and neck cancer, and gynecologic malignancies. Notably, Talimogene laherparepvec (T-VEC) and Oncorine have. been approved for advanced melanoma and nasopharyngeal carcinoma, respectively. However, adverse effects have been reported in some cases, including flu-like symptoms and rare instances of severe complications such as fistula formation. Although no OV has been approved specifically for breast cancer treatment, ongoing preclinical clinical trials focus on four groups of viruses. While mild adverse effects like low-grade fever and nausea have been observed, the effectiveness of OV monotherapy in breast cancer remains insufficient. Combination strategies integrating OVs with chemotherapy, radiotherapy, or immunotherapy, show promise in improving therapeutic outcomes. Oncolytic virus therapy holds substantial potential in breast cancer treatment, demonstrating safety in trials. Multi-approach strategies combining OVs with conventional therapies exhibit more promising therapeutic effects than monotherapy, signalling a hopeful future for OV-based breast cancer treatments.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1375433/fullbreast cancerimmunotherapyoncolytic virus therapytumour microenvironmentTME |
| spellingShingle | Hanna Chowaniec Antonina Ślubowska Magdalena Mroczek Martyna Borowczyk Małgorzata Braszka Grzegorz Dworacki Grzegorz Dworacki Paula Dobosz Paula Dobosz Mateusz Wichtowski New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy Frontiers in Immunology breast cancer immunotherapy oncolytic virus therapy tumour microenvironment TME |
| title | New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy |
| title_full | New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy |
| title_fullStr | New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy |
| title_full_unstemmed | New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy |
| title_short | New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy |
| title_sort | new hopes for the breast cancer treatment perspectives on the oncolytic virus therapy |
| topic | breast cancer immunotherapy oncolytic virus therapy tumour microenvironment TME |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1375433/full |
| work_keys_str_mv | AT hannachowaniec newhopesforthebreastcancertreatmentperspectivesontheoncolyticvirustherapy AT antoninaslubowska newhopesforthebreastcancertreatmentperspectivesontheoncolyticvirustherapy AT magdalenamroczek newhopesforthebreastcancertreatmentperspectivesontheoncolyticvirustherapy AT martynaborowczyk newhopesforthebreastcancertreatmentperspectivesontheoncolyticvirustherapy AT małgorzatabraszka newhopesforthebreastcancertreatmentperspectivesontheoncolyticvirustherapy AT grzegorzdworacki newhopesforthebreastcancertreatmentperspectivesontheoncolyticvirustherapy AT grzegorzdworacki newhopesforthebreastcancertreatmentperspectivesontheoncolyticvirustherapy AT pauladobosz newhopesforthebreastcancertreatmentperspectivesontheoncolyticvirustherapy AT pauladobosz newhopesforthebreastcancertreatmentperspectivesontheoncolyticvirustherapy AT mateuszwichtowski newhopesforthebreastcancertreatmentperspectivesontheoncolyticvirustherapy |